Sigong Zhang

12PUBLICATIONS
3CO-AUTHORS
Molecular targetsMolecular medicineImmunogenetics (incl. genetic immunology)AllergyAutoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jul 15, 2026
Targeting ERK1/2 attenuates neutrophil extracellular traps-mediated pro-inflammatory and pro-fibrotic effects in myositis-associated interstitial lung disease.

|May 07, 2026
Nerandomilast alleviates myositis-associated interstitial lung disease by modulating the non-Smad signalling pathway and activating the cAMP-PKA-RhoA pathway.

|Apr 21, 2026
Serum Endothelin-1 Is Associated With Interstitial Lung Disease in Idiopathic Inflammatory Myopathy.

|Apr 21, 2026
Reply.

|Feb 15, 2026
Anlotinib ameliorates myositis-associated interstitial lung disease (MAILD) via suppression of the NETs-PI3K/Akt-driven epithelial-mesenchymal transition.

Jumei Yang, Hui Chai, Jiarui Zhu

|Nov 25, 2025
Interleukin-33 Promotes Interstitial Lung Disease in Idiopathic Inflammatory Myopathy Via ERK-Mediated Epithelial-Mesenchymal Transition: ERK as a Potential Therapeutic Target.

Jumei Yang, Wenjun Li, Jiarui Zhu

Pageof 2

Frequent Collaborators

2 joint publications

Jiarui Zhu

1 joint publications

Haili Shen

1 joint publications

Yingyue Feng